

TITLE: NEW METHOD FOR IDENTIFYING RISK FACTORS ASSOCIATED TO HYPERTENSION

FIELD OF INTEREST

Biotechnology (Renal, Cardiovascular)

CLINICAL NEED

Hypertension is a multi-factorial disease of increasing prevalence and a major risk factor for cardiovascular (CV) mortality even in the presence of an apparently adequate treatment.

Chronic suppression of the renin–angiotensin system (RAS) has been shown to facilitate blood pressure (BP) control, to prevent the development of new-onset albuminuria and to diminish the amount of urinary albumin in patients with persistent high or very high albuminuria. However, in a relevant sub-group of patients under chronic RAS suppression high albuminuria exists, either as maintained (MHA) or as de novo developed (dnA). This group of patients probably represents those at the highest risk of progression of CV and renal disease. The discovery of predictors of progression or development of albuminuria during chronic RAS suppression is warranted as a helpful tool to detect where pharmacological therapy must be intensified and also where new drugs should be primarily tested.

DESCRIPTION OF THE INVENTION

The invention relates to a prognostic method and kit for identifying albuminuria development risk, renal injury risk and cardiovascular risk in a hypertensive human subject. This prognostic method comprises assessing the concentration of at least one of the compounds selected from the group consisting of 9 metabolites.

TECHNOLOGY KEYWORDS

Metabolites, albuminuria, hypertension, cardiovascular risk

IPR STATUS

Patent application number: P201630559// PCT/ES2017/070265.

Applicants: IIS-FJD, IMAS12 (FIBH12O), FUNDACION DE INVESTIGACION HOSPITAL NACIONAL DE PARAPLEJICOS DE TOLEDO.

TYPE AND ROLE OF PARTNER

Looking for technological partners for going through clinical trials as well as commercial partners interested in licensing.

Contact details:

Innovation Unit
e-mail: irene.ruano@fjd.es
Phone number: 0034-915504800 Ext.3455